Abfero pharmaceuticals
Pipeline
Developing
small molecule
iron chelators
Our therapeutic platform addresses transfusional iron overload (TIO) and iron accumulation associated with diseases of aging. With SP-420’s ability to cross the blood-brain and blood-retinal barriers, we’re expanding our scope to local iron overload implicated in Parkinson’s and other neurodegenerative diseases and in retinal degeneration.
SP-420 Safety Studies
AbFero has completed three safety studies with SP-420 to date:
Phase 1a in healthy volunteers (n=24)
Single, ascending doses ranging from 1.67 to 13.2 mg/kg
Phase 1b in patients with transfusion-dependent β-thalassemia (n=24)
Open-label, dose-escalation 1.5 to 24 mg/kg/day per day for up to 28 days
Phase 1c in healthy volunteers (n=12) to support TIW dosing in TIO
Single, ascending doses of 28, 56, and 84 mg/kg dose with food
Clinical Stage with Multiple Indications
- Transfusional Iron Overload
- Retinal Degeneration
- Parkinson’s Disease
- Ischemia Reperfusion
SP-420 INdications
AbFero Phamaceuticals, Inc
Dedicated to treating diseases of iron overload
Copyright © AbFero Pharmaceuticals | Privacy Policy & Terms of Use